• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    ARS Pharmaceuticals, Inc. - Common Stock (NQ: SPRY )

    17.04 +0.90 (+5.58%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about ARS Pharmaceuticals, Inc. - Common Stock

    < Previous 1 2 3 4 Next >
    ARS Pharmaceuticals Announces Conference Call and Webcasts for its Third Quarter 2024 Financial Results and Presentations at Upcoming Conferences
    Third Quarter Earnings Conference Call to be Held on November 13 at 8:00 a.m. ET 
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    Where ARS Pharmaceuticals Stands With Analysts
    Via Benzinga
    Analyst Ratings For ARS Pharmaceuticals
    Via Benzinga
    Looking Into ARS Pharmaceuticals's Recent Short Interest
    Via Benzinga
    ARS Pharmaceuticals Announces U.S. Availability of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
    Visit neffy.com to “Get neffy Now” and access the comprehensive patient assistance programs available through neffyConnect 
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    ARS Pharmaceuticals Submits sNDA to FDA for neffy® 1 mg Dose for Pediatric Patients with Type I Allergic Reactions Who Weigh 15 to 30 kg (33-66 lbs.)
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    ARS Pharmaceuticals Launches Pre-Ordering Services for neffy® to Help Patients Access the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    EURneffy (adrenaline nasal spray) Approved in the EU as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    Newly Approved ARS Pharmaceuticals' Needle-Free Neffy Offers Convenience Over EpiPen For Allergic Reaction, But Real-World Efficacy Questioned
    Neffy, a nasal spray alternative to EpiPen, offers convenience and longer shelf life but faces skepticism from allergists due to limited real-world testing and potential insurance hurdles. 
    Via Benzinga
    ARS Pharmaceuticals 'Neffy Uniquely Positioned With Potential To Change Allergy Treatment Paradigm For First Time In 40 years:' Analyst
    "FDA recently approved ARS Pharmaceuticals' neffy nasal spray for emergency allergic reactions, offering an alternative to epinephrine autoinjectors like EpiPen. Cantor sees strong market potential and... 
    Via Benzinga
    Fabrinet Posts Strong Earnings, Joins Amer Sports, Hawaiian Holdings And Other Big Stocks Moving Higher On Tuesday
    Via Benzinga
    Loar Holdings Posts Upbeat Results, Joins Nvidia, Clean Energy Fuels, Penumbra And Other Big Stocks Moving Higher On Tuesday
    Via Benzinga
    FDA Approves ARS Pharma's Once Rejected Neffy Nasal Spray Alternative To EpiPen For Emergency Allergy Treatment
    FDA approves ARS Pharmaceuticals' Neffy, the first nasal spray for treating severe allergic reactions and anaphylaxis. This new option offers a non-injection alternative to epinephrine autoinjectors,... 
    Via Benzinga
    Exposures Product Safety
    ARS Pharmaceuticals Receives FDA Approval of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    ARS Pharmaceuticals to Participate in the 2024 Wedbush PacGrow Healthcare Conference
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    ARS Pharmaceuticals Provides Business Highlights and Reports Second Quarter 2024 Financial Results
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    ARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis)
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    SPRY Stock Earnings: ARS Pharmaceuticals Meets EPS for Q1 2024
    SPRY stock results show that ARS Pharmaceuticals met analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace
    ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    Top 5 Health Care Stocks That May Plunge In March
    As of March 28, 2024, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. 
    Via Benzinga
    SPRY Stock Earnings: ARS Pharmaceuticals Beats EPS for Q4 2023
    SPRY stock results show that ARS Pharmaceuticals beat analyst estimates for earnings per share the fourth quarter of 2023. 
    Via InvestorPlace
    Wall Street Favorites: 3 Under-$10 Stocks with Strong Buy Ratings for March 2024
    U.S. equities market is rallying, but there are still interesting investments to make, especially for these strong-buy stocks under $10. 
    Via InvestorPlace
    ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor Day
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    Allergic Reaction Focused ARS Pharmaceuticals' Lead Candidate Shows Efficacy In Skin Disorder
    ARS Pharmaceuticals reports Phase 2 study results for neffy (epinephrine nasal spray) treating chronic spontaneous urticaria. Significant improvements in itch, hives, and erythema scores were observed... 
    Via Benzinga
    ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.